Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. reduced its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Rating) by 39.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,066 shares of the pharmaceutical company’s stock after selling 8,387 shares during the quarter. Pacer Advisors Inc.’s holdings in Vertex Pharmaceuticals were worth $3,410,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of VRTX. Norges Bank acquired a new position in shares of Vertex Pharmaceuticals in the fourth quarter worth $588,506,000. Alliancebernstein L.P. grew its position in shares of Vertex Pharmaceuticals by 15.2% during the fourth quarter. Alliancebernstein L.P. now owns 10,443,771 shares of the pharmaceutical company’s stock worth $2,293,452,000 after buying an additional 1,374,923 shares in the last quarter. Vaughan Nelson Investment Management L.P. acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth about $202,855,000. Lazard Asset Management LLC grew its position in shares of Vertex Pharmaceuticals by 451.9% during the fourth quarter. Lazard Asset Management LLC now owns 915,720 shares of the pharmaceutical company’s stock worth $201,090,000 after buying an additional 749,784 shares in the last quarter. Finally, Epoch Investment Partners Inc. grew its position in shares of Vertex Pharmaceuticals by 159.0% during the fourth quarter. Epoch Investment Partners Inc. now owns 819,848 shares of the pharmaceutical company’s stock worth $180,038,000 after buying an additional 503,347 shares in the last quarter. Institutional investors and hedge funds own 89.84% of the company’s stock.

In other news, Director Yuchun Lee sold 2,000 shares of the business’s stock in a transaction dated Monday, April 4th. The shares were sold at an average price of $267.72, for a total transaction of $535,440.00. Following the transaction, the director now directly owns 1,875 shares in the company, valued at $501,975. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Chairman Jeffrey M. Leiden sold 15,789 shares of the firm’s stock in a transaction dated Wednesday, April 13th. The shares were sold at an average price of $289.04, for a total transaction of $4,563,652.56. Following the completion of the sale, the chairman now owns 74,160 shares of the company’s stock, valued at approximately $21,435,206.40. The disclosure for this sale can be found here. In the last three months, insiders sold 36,683 shares of company stock worth $10,227,645. Corporate insiders own 0.40% of the company’s stock.

VRTX has been the subject of a number of analyst reports. Robert W. Baird downgraded Vertex Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $250.00 price objective for the company. in a research report on Friday, May 6th. Cowen boosted their target price on shares of Vertex Pharmaceuticals from $305.00 to $310.00 and gave the stock an “outperform” rating in a research note on Monday, June 13th. StockNews.com assumed coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, March 31st. They set a “strong-buy” rating for the company. Maxim Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $325.00 target price for the company in a research note on Wednesday, June 1st. Finally, Cowen boosted their target price on shares of Vertex Pharmaceuticals from $305.00 to $310.00 in a research note on Monday, June 13th. Seven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $282.61.

VRTX stock opened at $283.50 on Friday. The company has a market cap of $72.51 billion, a price-to-earnings ratio of 29.84, a price-to-earnings-growth ratio of 2.00 and a beta of 0.55. The company has a fifty day moving average price of $264.54 and a 200 day moving average price of $246.42. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.75 and a quick ratio of 4.60. Vertex Pharmaceuticals Incorporated has a 12 month low of $176.36 and a 12 month high of $292.75.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Rating) last announced its earnings results on Thursday, May 5th. The pharmaceutical company reported $3.16 earnings per share for the quarter, missing the consensus estimate of $3.17 by ($0.01). The business had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.07 billion. Vertex Pharmaceuticals had a return on equity of 32.24% and a net margin of 30.84%. Vertex Pharmaceuticals’s quarterly revenue was up 21.6% on a year-over-year basis. During the same quarter last year, the company posted $2.54 EPS. As a group, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 12.47 earnings per share for the current year.

About Vertex Pharmaceuticals (Get Rating)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Read More

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.